{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:54:13Z","timestamp":1765382053525,"version":"3.46.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Oriental Talent Program","award":["CYQN2023030"],"award-info":[{"award-number":["CYQN2023030"]}]},{"name":"Academician Expert Workstation Grants in Shanghai Yuansong Biotechnology Co.","award":["19R1002275468, 20R9004076411, 21R4007547098, S182023110190129357"],"award-info":[{"award-number":["19R1002275468, 20R9004076411, 21R4007547098, S182023110190129357"]}]},{"name":"Shanghai science and technology support project on biomedicine in the action plan of Science and Technology innovation","award":["19431904200"],"award-info":[{"award-number":["19431904200"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173343"],"award-info":[{"award-number":["82173343"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27137-z","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:46:50Z","timestamp":1765381610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic efficacy of oncolytic adenovirus YSCH-01 in osteosarcoma evaluated in PDX and CDX mouse models"],"prefix":"10.1038","volume":"15","author":[{"given":"Hanqiang","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonggang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-ping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiz Khuram","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-long","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"27137_CR1","doi-asserted-by":"crossref","unstructured":"Hannah, C. B. et al. Osteosarcoma.  Nat. Rev. Dis. Primers 8, 1 (2022).","DOI":"10.1038\/s41572-022-00411-4"},{"key":"27137_CR2","doi-asserted-by":"crossref","unstructured":"Theresa, H. M. K., Renata, A. & Elysia, M. A. Survival trends among adolescents and young adults diagnosed with cancer in the united states: comparisons with children and older adults. J. Clin. Oncol. 42, 6 (2023).","DOI":"10.1200\/JCO.23.01367"},{"issue":"10","key":"27137_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","volume":"18","author":"J Gill","year":"2021","unstructured":"Gill, J. & Gorlick, R. Advancing therapy for osteosarcoma. Nat. Rev.  Clin. Oncol. 18 (10), 609\u2013624 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"14","key":"27137_CR4","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.7150\/thno.72800","volume":"12","author":"M Panagi","year":"2022","unstructured":"Panagi, M., Pilavaki, P., Constantinidou, A. & Stylianopoulos, T. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. Theranostics 12 (14), 6106\u20136129 (2022).","journal-title":"Theranostics"},{"issue":"5","key":"27137_CR5","doi-asserted-by":"publisher","first-page":"189171","DOI":"10.1016\/j.bbcan.2024.189171","volume":"1879","author":"P Yan","year":"2024","unstructured":"Yan, P., Wang, J., Yue, B. & Wang, X. Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma. Biochim. Et Biophys. Acta Rev. Cancer. 1879 (5), 189171 (2024).","journal-title":"Biochim. Et Biophys. Acta Rev. Cancer"},{"key":"27137_CR6","doi-asserted-by":"crossref","unstructured":"Alannah, S. et al. Future directions in the treatment of osteosarcoma. Cells 10, 1 (2021).","DOI":"10.3390\/cells10010172"},{"issue":"2","key":"27137_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.4143\/crt.2023.999","volume":"56","author":"M Hana Lim","year":"2024","unstructured":"Hana Lim, M. et al. Tandem High-Dose chemotherapy increases the risk of secondary malignant neoplasm in pediatric solid tumors. Cancer Res. Treat. 56 (2), 642\u2013651 (2024).","journal-title":"Cancer Res. Treat."},{"issue":"2","key":"27137_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4143\/crt.2021.178","volume":"54","author":"HY Ju","year":"2022","unstructured":"Ju, H. Y. et al. Vincristine, Irinotecan, and Temozolomide as a salvage regimen for relapsed or refractory sarcoma in children and young adults. Cancer Res. Treat. 54 (2), 563\u2013571 (2022).","journal-title":"Cancer Res. Treat."},{"issue":"1","key":"27137_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4143\/crt.2021.320","volume":"54","author":"H Zhengbo","year":"2022","unstructured":"Zhengbo, H. et al. Enrichment of Wee1\/CDC2 and NF-\u03baB signaling pathway constituents mutually contributes to CDDP resistance in human osteosarcoma. Cancer Res. Treat. 54 (1), 277\u2013293 (2022).","journal-title":"Cancer Res. Treat."},{"issue":"2","key":"27137_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1200\/JCO.2017.75.2717","volume":"36","author":"J Crompton","year":"2018","unstructured":"Crompton, J. et al. Local control of soft tissue and bone sarcomas. J. Clin. Oncol. 36 (2), 111\u2013117 (2018).","journal-title":"J. Clin. Oncol."},{"key":"27137_CR11","doi-asserted-by":"crossref","unstructured":"Hannah, C. et al. Osteosarcoma.  Nat. Rev. Dis. Primers 8 (1), 77  (2022).","DOI":"10.1038\/s41572-022-00411-4"},{"issue":"27","key":"27137_CR12","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","volume":"33","author":"M Isakoff","year":"2015","unstructured":"Isakoff, M., Bielack, S., Meltzer, P. & Gorlick, R. Osteosarcoma: current treatment and a collaborative pathway to success. J. Clin. Oncol. 33 (27), 3029\u20133035 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"27137_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12951-023-01826-1","volume":"21","author":"P Shi","year":"2023","unstructured":"Shi, P. et al. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. J. Nanobiotechnol. 21 (1), 103 (2023).","journal-title":"J. Nanobiotechnol."},{"key":"27137_CR14","unstructured":"Lisa, M. et al. Frequency of pathogenic germline variants in Cancer-Susceptibility genes in patients with osteosarcoma. JAMA Oncol. 6, 5  (2020)."},{"issue":"1","key":"27137_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-024-03319-w","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Single-cell and Spatial transcriptomics reveal metastasis mechanism and microenvironment remodeling of lymph node in osteosarcoma. BMC Med. 22 (1), 200 (2024).","journal-title":"BMC Med."},{"issue":"19","key":"27137_CR16","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1158\/1078-0432.CCR-24-1317","volume":"30","author":"M Lizardo","year":"2024","unstructured":"Lizardo, M. et al. Pharmacologic Inhibition of eIF4A blocks NRF2 synthesis to prevent osteosarcoma metastasis. Clin. Cancer Res. 30 (19), 4464\u20134481 (2024).","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"27137_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"S Russell","year":"2012","unstructured":"Russell, S., Peng, K. & Bell, J. Oncolytic virotherapy. Nat. Biotechnol. 30 (7), 658\u2013670 (2012).","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"27137_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"P Bommareddy","year":"2018","unstructured":"Bommareddy, P., Shettigar, M. & Kaufman, H. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18 (8), 498\u2013513 (2018).","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"27137_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"S Shalhout","year":"2023","unstructured":"Shalhout, S., Miller, D., Emerick, K. & Kaufman, H. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20 (3), 160\u2013177 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"27137_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-024-01946-8","volume":"23","author":"M Toulmonde","year":"2024","unstructured":"Toulmonde, M. et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide. Mol. Cancer. 23 (1), 38 (2024).","journal-title":"Mol. Cancer"},{"issue":"5","key":"27137_CR21","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.ymthe.2020.02.017","volume":"28","author":"M Ferguson","year":"2020","unstructured":"Ferguson, M. et al. Transient Inhibition of PI3K\u03b4 enhances the therapeutic effect of intravenous delivery of oncolytic vaccinia virus. Mol. Therapy: J. Am. Soc. Gene Therapy. 28 (5), 1263\u20131275 (2020).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"issue":"10","key":"27137_CR22","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/mt.2009.194","volume":"17","author":"C Willmon","year":"2009","unstructured":"Willmon, C. et al. Cell carriers for oncolytic viruses: fed ex for cancer therapy. Mol. Therapy: J. Am. Soc. Gene Therapy. 17 (10), 1667\u20131676 (2009).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"issue":"11","key":"27137_CR23","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1038\/mt.2013.179","volume":"21","author":"C Kim","year":"2013","unstructured":"Kim, C. et al. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy. Mol. Therapy: J. Am. Soc. Gene Therapy. 21 (11), 2063\u20132073 (2013).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"issue":"5","key":"27137_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ijc.28450","volume":"134","author":"V Jennings","year":"2014","unstructured":"Jennings, V. et al. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in Ascites. Int. J. Cancer. 134 (5), 1091\u20131101 (2014).","journal-title":"Int. J. Cancer"},{"issue":"9","key":"27137_CR25","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1158\/1078-0432.CCR-10-3266","volume":"17","author":"E Ilett","year":"2011","unstructured":"Ilett, E. et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin. Cancer Res. 17 (9), 2767\u20132776 (2011).","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"27137_CR26","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"H Kaufman","year":"2015","unstructured":"Kaufman, H., Kohlhapp, F. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discovery. 14 (9), 642\u2013662 (2015).","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"4","key":"27137_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"E Kelly","year":"2007","unstructured":"Kelly, E. & Russell, S. History of oncolytic viruses: genesis to genetic engineering. Mol. Therapy: J. Am. Soc. Gene Therapy. 15 (4), 651\u2013659 (2007).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"27137_CR28","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.semcancer.2021.06.021","volume":"86","author":"X Ma","year":"2022","unstructured":"Ma, X., Hill, B., Hoang, T. & Wen, F. Virus-inspired strategies for cancer therapy. Sem. Cancer Biol. 86, 1143\u20131157 (2022).","journal-title":"Sem. Cancer Biol."},{"issue":"1","key":"27137_CR29","first-page":"vdad117","volume":"28","author":"HH Shan Jiang","year":"2023","unstructured":"Shan Jiang, H. H. & Chai, X. L. Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma. Neurooncol. Adv. 28 (1), vdad117 (2023).","journal-title":"Neurooncol. Adv."},{"issue":"1","key":"27137_CR30","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12967-023-04539-z","volume":"21","author":"WY Xu He","year":"2023","unstructured":"Xu He, W. Y. et al. Potent antitumor efficacy of human dental pulp stem cells armed with YSCH\u201301 oncolytic adenovirus. J. Transl. Med. 21 (1), 688 (2023).","journal-title":"J. Transl. Med."},{"issue":"5","key":"27137_CR31","doi-asserted-by":"publisher","first-page":"e008999","DOI":"10.1136\/jitc-2024-008999","volume":"12","author":"Y He","year":"2024","unstructured":"He, Y. et al. Preliminary efficacy and safety of YSCH\u00ad01 in patients with advanced solid tumors: an investigator-\u00adinitiated trial. J. Immunother. Cancer 12 (5), e008999 (2024).","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"27137_CR32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2217\/imt-2019-0217","volume":"12","author":"MH Abdolvahab","year":"2020","unstructured":"Abdolvahab, M. H. et al. Interferons: role in cancer therapy. Immunotherapy 12 (11), 833\u2013855 (2020).","journal-title":"Immunotherapy"},{"key":"27137_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1006\/scbi.2000.0315","volume":"10","author":"EC Borden","year":"2000","unstructured":"Borden, E. C., Lindner, D., Dreicer, R., Hussein, M. & Peereboom, D. Secondgeneration interferons for cancer: clinical targets. Semin. Cancer Biol. 10, 125\u2013144 (2000).","journal-title":"Semin. Cancer Biol."},{"issue":"27","key":"27137_CR34","doi-asserted-by":"publisher","first-page":"16072","DOI":"10.1073\/pnas.1918937117","volume":"117","author":"I Jason","year":"2020","unstructured":"Jason, I. et al. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc. Natl. Acad. Sci. U S A 117 (27), 16072\u201316082 (2020).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"27137_CR35","doi-asserted-by":"crossref","unstructured":"Serge, Y.  Fuchs Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J. Interferon Cytokine Res. 33, 211\u2013225 (2013).","DOI":"10.1089\/jir.2012.0117"},{"issue":"8","key":"27137_CR36","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-16-1386","volume":"23","author":"KJ Zhang","year":"2017","unstructured":"Zhang, K. J. et al. A potent in vivo antitumor efficacy of novel Recombinant type I interferon. Clin. Cancer Res. 23 (8), 2038\u20132049 (2017).","journal-title":"Clin. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27137-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27137-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27137-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:46:52Z","timestamp":1765381612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27137-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27137"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27137-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kang-jian Zhang and Xian-long Fang hold an ownership interest (including patents of YSCH-01) in Yuansong Biotechnology. Other authors report no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol of the human tumor tissues study was approved by the Ethics Committee of Shanghai Sixth People\u2019s Hospital (NO. 2020\u2009\u2212\u2009131). All methods were carried out in accordance with relevant guidelines and regulations. We followed the ethical guidelines outlined in the Helsinki Declaration for conducting research involving human subjects. We guaranteed the protection of data anonymity and confidentiality and utilizing it solely for purposes stated above. Informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethical approval"}},{"value":"All animal experimental protocols were approved by the Experimental Animal Care Commission of Shanghai LIDE biotech Co. Ltd (the reference number LDIACUC 006). All methods of animal study were carried out in accordance with relevant guidelines and regulations. This study is reported in accordance with the ARRIVE guidelines. Mice were monitored every other day for humane endpoints, specifically tumor size, activity levels, and weight loss exceeding 15%. At the time of sacrifice, none of the animals had reached these humane endpoints. The mice were euthanized in a CO\u2082 environment via cervical dislocation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal ethics approval"}}],"article-number":"43565"}}